Previous Seminars
- January 25, 2021
- Control of antimicrobial resistance in low- and middle-income countries
OLIVIER VANDENBERG School of Public Health, Université Libre de Bruxelles (ULB); Division of Infection & Immunity, UCL, London, UK
- January 18, 2021
- COVID-19 mRNA vaccines: What do we know about their safety and how do we mitigate the risks?
JEAN-MICHEL DOGNÉ Head of the Department of Pharmacy at the University of Namur, Member of the EMA’s Pharmacovigilance Risk Assessment Committee and WHO’s Global Advisory Committee on Vaccine Safety
- December 14, 2020
- Mental Models and Learning: The Case of Base-Rate Neglect
SEVGI YUKSEL Assistant Professor of Economics at University of California Santa Barbara
REGISTRATION
- December 07, 2020
- Public money for clinical research in oncology: a necessity
LYDIE MEHEUS Managing Director, Anticancer Fund
REGISTRATION
- November 23, 2020
- Who should get it first? Public preferences for distributing a COVID-19 vaccine
SANDY TUBEUF Professor of Health Economics, UCLouvain
REGISTRATION
- November 16, 2020
- Entry decisions and asymmetric competition between non-profit and for-profit homes in the long-term care market
Iris Kesternich Professor of Behavioral Economics, KU Leuven
- October 26, 2020
- Real-time epidemiology to monitor COVID-19: from data-analysis to communication and decision-making
Marius Gilbert Head of the Spatial Epidemiology Lab, ULB Research director at FNRS-FRSS
- October 12, 2020
- La saga des herbes chinoises, une lecon de sante publique
Jean-Louis Vanherweghem Professor Emeritus of the ULB, Member of the Royal Academy of Medicine
- October 12, 2020
- La saga des herbes chinoises, une lecon de sante publique
Marius Gilbert FNRS Research director at the ULB Head of the spatial epidemiology Lab Member of the former GEES
- October 05, 2020
- Modelling the SARS-CoV-2 pandemic - focus on Belgium
Niel Hens Professor at UAntwerpen and UHasselt, Member of the former Group of Experts for the Exit Strategy (GEES)s
- September 28, 2020
- Innovative medicines: reconciling public health and business
Ri De Ridder former director-general at the National Institute for Health and Disability Insurance (Inami/Riziv), i.a. managing the medicines reimbursement process, and current president on the board of directors for Doctors of the World Belgium
- February 24, 2020
- Development of a priority-setting algorithm for vaccines: a discrete choice experiment
Jeroen Luyten Associate Professor of Health Economics at the Leuven Institute for Healthcare Policy and a visiting fellow at the London School of Economics
- February 03, 2020
- Augmented Medicine - The way Artificial Intelligence is reshaping clinical practice
Giovanni Briganti Associate Lecturer of Medical Technology (AI & Health) at ULB and Lecturer of Physiology at the ES Santé School of Health
- January 20, 2020
- The economic cost of air pollution: evidence from Europe
Antoine Dechezleprêtre Senior Economist at OECD
- December 09, 2019
- “Ethics, markets and organizations” (joint work with Jean Tirole)
Mathias Dewatripont Former Executive Director of the National Bank of Belgium and Dean of the Solvay Brussels School of Economics and Management
- November 25, 2019
- A new year, a new you? A two-selves model of within-individual variation in food purchases
Bram De Rock Professor in Mathematical Economics at ULB and KU Leuven; Director of ECARES
- November 04, 2019
- The importance of social network in health, health care and in health policies
Vincent Lorant Professor at Faculty of Public Health, UCL
- October 21, 2019
- The economic cost of air pollution: Evidence from Europe
Antoine Dechezleprêtre Senior Economist at OECD
- September 30, 2019
- Vaccines hesitancy
Marie Neunez Research fellow at Institute for Interdisciplinary Innovation in healthcare (I3h)
- June 03, 2019
- Effects of physician-industry interactions on treatments: the case of heart attacks
Sofia Amaral-Garcia Postdoc Researcher at Hasselt University, in the research group Economics and Public Policy
- May 16, 2019 - June 03, 2019
- Opioid analgesics consumption in France
Ilaria Natali Teaching Assistant for Advanced Industrial Organization, ULB
- April 29, 2019
- Market access of pharmaceutical innovation: international R&D, high prices and national competent authorities
Philippe Van Wilder Professor in health economics and HTA at Ecole de Santé Publique, ULB
- February 18, 2019
- Subsidized Health Insurance and Healthcare Utilization: new evidence from a large-scale field experiment
Raf Van Gestel Assistant Professor, Erasmus School of Economics & Erasmus School of Health Policy and Management
- January 21, 2019
- Therapeutic drug monitoring of biologics: where to start, where to end?
Lynda Grine Doctor-assistant at Ghent University and Research Associate at the Dermatology Department of Ghent University Hospital
- December 10, 2018
- Scientific, regulatory, and economic challenges facing the implementation of phage therapy and the Belgian model.
Bob Blasdel Research Director for Vesale Pharma
- November 30, 2018
- The case of a multi-drug resistant infection
- November 26, 2018
- Precision oncology: how to structure the continuum of clinical research into healthcare for rationale access to anti-cancer treatment
Denis Lacombe Director General of the European Organisation for Research and Treatment of Cancer
- November 12, 2018
- Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets
Georges Siotis Associate Professor at the Economics Department of Universidad Carlos III de Madrid and CEPR Research Fellow
- October 29, 2018
- Towards new partnerships in the healthcare sector
Wim Van Haverbeke Professor of Innovation Management & Strategy at the Hasselt University
- October 08, 2018
- Vaccines: how to value them, how to price them?
Michel Dewilde MDWConsultant, former Senior Vice President R&D, Sanofi Pasteur
- October 01, 2018
- Measuring mortality in conflicts and disasters: why does it matter?
Debarati Guha Director of the Centre for Research on the Epidemiology of Disasters (CRED) and Professor at the School of Public Health (UCL)
- June 04, 2018
- Public funding and influential health research: Evidence from the US and the UK
Charitini Stavropoulou Senior Lecturer in Health Management at the School of Health Sciences (City University of London)
- May 28, 2018
- Endogenous childlessness and stages of development
Paula E. Gobbi Member of ECARES (ULB) and CEPR
- May 07, 2018
- Translational hepatology: scientific, economic and financial challenges
Etienne Sokal Professor at UCLouvain, Hepatologist at Cliniques Universitaires Saint Luc and Founder of Promethera Biosciences
- April 23, 2018
- Novel approaches to pricing and reimbursement for innovative medicines
Lieven Annemans Professor of Health Economics at the Medical Faculty of Ghent University
- April 09, 2018
- Value assessment and reimbursement: the (special?) case of orphan drugs
Steven Simoens Professor at the Faculty of Pharmaceutical Sciences (KU Leuven)
- March 19, 2018
- Subgroup and post-hoc analyses in clinical trials: the truth lies in the eye of the beholder
Bruno Flamion MD, PhD, Professor of Clinical Pharmacology (UNamur) and VP Head Strategic Development (Idorsia Pharmaceuticals)
- March 05, 2018
- Are ideas getting harder to find?
Øyvind Aas Post-doctoral researcher at ECARES, ULB
- February 26, 2018
- Economic value of vaccines for the developing world: different perspectives
Bill Hausdorff Senior Lecturer at Faculté de Médecine ULB, Independent Consultant
- February 12, 2018
- Awareness and AIDS: A Political Economy Perspective
by Gani Aldashev Professor at ULB
- January 29, 2018
- The opioid crisis: what went wrong? Crossing medical and economic perspectives.
Maurice Sosnowski MD, professor at ULB and Mathias Dewatripont PhD, Co-director of I3h, professor of Economics at ULB
- January 15, 2018
- The Unexpected Consequences of Asymmetric Competition: An Application to the Pharmaceutical Industry.
Micael Castanheira PhD, Director for Research at FRS-FNRS
- December 11, 2017
- Redefining health policy for effective coverage: Where do we stand in Tuberculosis control?
Samia Laokri PhD, Assistant Professor at ULB
- November 27, 2017
- Do regulatory agencies hamper therapeutic innovation?
Mathias Dewatripont PhD, Co-director of I3h, professor of Economics at ULB
- November 13, 2017
- The changing face of clinical trials and their impact on industrial R&D
Michel Goldman MD, PhD, Co-director I3h , professor at ULB and Chief Editor of ‘Frontiers in Medicine’
- October 30, 2017
- Intellectual property policies in early-phase research in public-private partnerships
Hilde Stevens PhD, Baillet Latour Chair in Translational Medicine, Associate Professor (ULB)
